Use of SGLT2 inhibitors after bariatric/metabolic surgery: risk/benefit balance.

[en] Bariatric/metabolic surgery and sodium-glucose cotransporter 2 inhibitors (SGLT2is) are becoming increasingly popular for the management of overweight/obese patients with type 2 diabetes mellitus (T2DM). Consequently, the chance that a patient undergoing bariatric/metabolic surgery is also treated with an SGLT2i would be rather common in clinical practice. Both risks and benefits have been reported. On the one hand, several cases of euglycemic diabetic ketoacidosis have been reported within the few days/weeks after bariatric/metabolic surgery. The causes are diverse but a drastic reduction in caloric (carbohydrate) intake most probably plays a crucial role. Thus, SGLT2is should be stopped a few days (and even more if a pre-operative restricted diet is prescribed to reduce liver volume) before the intervention and reintroduced only when the caloric (carbohydrate) intake is sufficient. On the other hand, SGLT2is may exert a favorable effect to reduce the risk of postprandial hypoglycemia, a complication reported among patients who have been treated with bariatric/metabolic surgery. An increased hepatic glucose production and a reduced production of interleukin-1β have been proposed as possible underlying mechanisms for this protective effect. Finally, whether SGLT2is could prolong diabetes remission following surgery and improve the prognosis of patients with T2DM who benefit from bariatric/metabolic surgery remains to be investigated.

Disciplines :

Endocrinology, metabolism & nutrition
Gastroenterology & hepatology
Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, André ; Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques ; Division of Clinical Pharmacology, Centre for Interdisciplinary Research on

Language :

English

Title :

Use of SGLT2 inhibitors after bariatric/metabolic surgery: risk/benefit balance.

Publication date :

26 May 2023

Journal title :

Diabetes and Metabolism

ISSN :

1262-3636

eISSN :

1878-1780

Publisher :

Elsevier Masson, Paris, Fr

Volume :

Issue :

Pages :

351

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Available on ORBi :

since 13 July 2023

Statistics

Number of views

30 (2 by ULiège)

Number of downloads

1 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Scheen, A.J., Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nature Rev Endocrinol 16 (2020), 556–577.
Rubino, F., Nathan, D.M., Eckel, R.H., Schauer, P.R., Alberti, K.G., Zimmet, P.Z., et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a Joint statement by international diabetes organizations. Diabetes Care 39 (2016), 861–877.
Dutta, S., Kumar, T., Singh, S., Ambwani, S., Charan, J., Varthya, S.B., Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis. J Family Med Prim Care 11 (2022), 927–940.
Chauhan, S., Manov, A., Dhillon, G.S., Shah, P., Empagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus. Cureus, 15, 2023, e33892.
Iwasaki, Y., Sasabuchi, Y., Horikita, S., Furukawa, T., Shiotsuka, J., Lefor, A.K., et al. The effect of preoperative sodium-glucose cotransporter 2 inhibitors on the incidence of perioperative metabolic acidosis: a retrospective cohort study. BMC Endocr Disord, 22, 2022, 209.
Seki, H., Ideno, S., Shiga, T., Watanabe, H., Ono, M., Motoyasu, A., et al. Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: a systematic review of case reports. J Anesth, 2023, 10.1007/s00540-023-03174-8 Feb 27.
Mehta, P.B., Robinson, A., Burkhardt, D., Rushakoff, R.J., Inpatient perioperative euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter-2 inhibitors - lessons from a case series and strategies to decrease incidence. Endocr Pract 28 (2022), 884–888.
Iqbal, Q.Z., Mishiyev, D., Zia, Z., Ruggiero, R.A., Aftab, G., Euglycemic diabetic ketoacidosis with sodium-glucose cotransporter-2 inhibitor use post-bariatric surgery: a brief review of the literature. Cureus, 12, 2020, e10878.
Rizo, I.M., Apovian, C.M., Diabetic ketoacidosis post bariatric surgery. Front Endocrinol (Lausanne), 9, 2018, 812.
Lo, Y.T., Chen, K.H., Chang, P.C., Immediate euglycemic diabetic ketoacidosis after gastric bypass in a patient with type II diabetes. Obes Surg 31 (2021), 2787–2790.
Liu, Z., Xiao, L., Jin, C., Xiao, J., Zhao, W, Euglycaemic ketoacidosis due to extremely low-calorie intake and dehydration after laparoscopic sleeve gastrectomy in a patient with type 2 diabetes. Diabetes Metab Syndr Obes 15 (2022), 2377–2380.
Andalib, A., Elbahrawy, A., Alshlwi, S., Alkhamis, A., Hu, W., Demyttenaere, S., et al. Diabetic ketoacidosis following bariatric surgery in patients with type 2 diabetes. Diabetes Care 39 (2016), e121–e122.
Bonanni, F.B., Fei, P., Fitzpatrick, L.L., Normoglycemic ketoacidosis in a postoperative gastric bypass patient taking canagliflozin. Surg Obes Relat Dis 12 (2016), e11–e12.
Elasha, H., Elsheikh, A.M., Wafa, W., Meeran, K., SGLT2 inhibition may precipitate euglycemic DKA after bariatric surgery. Clin Diabetes Res 2 (2016), 40–42.
Dizon, S., Keely, E.J., Malcolm, J., Arnaout, A., Insights Into the recognition and management of SGLT2-inhibitor-associated ketoacidosis: it's not just euglycemic diabetic ketoacidosis. Can J Diabetes 41 (2017), 499–503.
Brown, F., McColl, T., Euglycemic diabetic ketoacidosis secondary to dapagliflozin use: a case report. J Emerg Med 54 (2018), 109–111.
van Niekerk, C., Wallace, J., Takata, M., Yu, R., Euglycaemic diabetic ketoacidosis in bariatric surgery patients with type 2 diabetes taking canagliflozin. BMJ Case Rep, 2018, 2018, bcr2017221527.
Lane, S., Paskar, D., Hamed, S., Goffi, A., When guidelines fail: euglycemic diabetic ketoacidosis after bariatric surgery in a patient taking a sodium-glucose cotransporter-2 inhibitor: a case report. A A Pract 11 (2018), 46–48.
Banakh, I., Kung, R., Gupta, S., Matthiesson, K., Tiruvoipati, R., Euglycemic diabetic ketoacidosis in association with dapagliflozin use after gastric sleeve surgery in a patient with type II diabetes mellitus. Clin Case Rep 7 (2019), 1087–1090.
Mendonça, F.M., Silva, M.M., Chaves, V., Souto, S., Freitas, P., Carvalho, D., Diabetic ketoacidosis after bariatric surgery: a case report. Rev Port Endocrinol Diabetes Metab 15 (2020), 178–181.
Khan, H.H., Dubiwa, E., Htet, Z.Y., Aung, T., Kavvoura, F., A case of refractory euglycemic diabetic ketoacidosis post elective bariatric surgery. Obesity Abstracts, 2, 2020, 10.1530/obabs.02.CD1.2 CD1.2 |.
Yared, K.E., Mancini, G.J., Euglycemic diabetic ketoacidosis associated with use of SGLT2 inhibitor after laparoscopic Roux-en-Y gastric bypass. Am Surg 87 (2021), 1997–1999.
Amianda, E.A., Gavigan, T.S., Talishinskiy, T., Ewing, D.R., Schmidt, H.J., Two cases of euglycemic diabetic ketoacidosis after bariatric surgery associated with sodium-glucose cotransporter-2 inhibitor use. Obes Surg 31 (2021), 3848–3850.
Kapila, V., Topf, J., Sodium-glucose co-transporter 2 inhibitor-associated euglycemic diabetic ketoacidosis after bariatric surgery: a case and literature review. Cureus, 13, 2021, e17093.
Smith, A., Holtrop, J., Sadoun, M., Post-operative euglycemic diabetic ketoacidosis in a patient with SGLT-2 inhibitor use and recent sleeve gastrectomy. Cureus, 13, 2021, e14297.
Alvares, K., Gidda, H., Proudan, N., Euglycemic diabetic ketoacidosis post bariatric surgery in type II DM in the setting of SGLT2-inhibitor use (Abstract). J Endocr Soc, 5, 2021, A380.
Vaghasia, N., Bononi, P., Custodio, P., Euglycemic diabetic ketoacidosis after bariatric surgery in association with use of SGLT2i (Abstract). J Endocr Society 6 (2022), A312–A3A3.
Aminian, A., Kashyap, S.R., Burguera, B., Punchai, S., Sharma, G., Froylich, D., et al. Incidence and clinical features of diabetic ketoacidosis after bariatric and metabolic surgery. Diabetes Care 39 (2016), e50–e53.
Thiruvenkatarajan, V., Meyer, E.J., Nanjappa, N., Van Wijk, R.M., Jesudason, D., Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review. Br J Anaesth 123 (2019), 27–36.
Gokhare Viswanath, N., Sharma, M., Bandlamudi, N., Idris, I., Singhal, R., Mahawar, K., et al. Sodium-glucose co-transporter-2 inhibitors induced diabetic ketoacidosis in patients undergoing bariatric surgery: a systematic review of case reports and case series. Obes Surg 33 (2023), 339–344.
Sharma, M., Nayar, R., Graham, Y., Parretti, H.M., Abbott, S., Tahrani, A., et al. Risk of harm from use of sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients pre or post bariatric surgery. Obes Surg 32 (2022), 2469–2470.
Eisenberg, D., Azagury, D.E., Ghiassi, S., Grover, B.T., Kim, J.J., ASMBS position statement on postprandial hyperinsulinemic hypoglycemia after bariatric surgery. Surg Obes Relat Dis 13 (2017), 371–378.
Llewellyn, D.C., Logan Ellis, H., Aylwin, S.J.B., Ostarijas, E., Green, S., Sheridan, W., et al. The efficacy of GLP-1RAs for the management of postprandial hypoglycemia following bariatric surgery: a systematic review. Obesity 31 (2023), 20–30.
Carpentieri, G.B., Goncalves, S., Mourad, W.M., Pinto, L.G.C., Zanella, M.T., Hypoglycemia post bariatric surgery: drugs with different mechanisms of action to treat a unique disorder. Arch Endocrinol Metab 67 (2023), 442–449.
Beshyah, S.A., First beneficial use of dapagliflozin for treatment of post-bariatric hypoglycemia: case report and hypothesis. Ibnosina J Med BS 8 (2016), 335–342.
Ciudin, A., Sanchez, M., Hernandez, I., Cordero, E., Fidilio, E., Comas, M., et al. Canagliflozin: a new therapeutic option in patients that present postprandial hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass: a pilot study. Obes Facts 14 (2021), 291–297.
Carpentieri, G.B., Goncalves, S., Casagrande, M.Z., Mourad, W.M., Pinto, L.G.C., Zanella, M.T., SGLT2 inhibition with empagliflozin as a possible therapeutic option for postprandial hypoglycemia after bariatric surgery. Obes Surg 32 (2022), 2664–2671.
Martinussen, C., Veedfald, S., Dirksen, C., Bojsen-Moller, K.N., Svane, M.S., Wewer Albrechtsen, N.J., et al. The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery. Am J Physiol Endocrinol Metab 318 (2020), E956–EE64.
Hepprich, M., Wiedemann, S.J., Schelker, B.L., Trinh, B., Starkle, A., Geigges, M., et al. Postprandial hypoglycemia in patients after gastric bypass surgery is mediated by glucose-induced IL-1beta. Cell Metab 31 (2020), 699–709 e5.
Ferreira, A., Emara, A.F.A., Herzig, D., Melmer, A., Vogt, A.P., Nakas, C.T., et al. Study protocol for a randomised, double-blind, placebo-controlled crossover trial assessing the impact of the SGLT2 inhibitor empagliflozin on postprandial hypoglycaemia after gastric bypass. BMJ Open, 12, 2022, e060668.
Tsilingiris, D., Koliaki, C., Kokkinos, A., Remission of type 2 diabetes mellitus after bariatric surgery: fact or fiction?. Int J Environ Res Public Health, 16, 2019, 3171.
Riddle, M.C., Cefalu, W.T., Evans, P.H., Gerstein, H.C., Nauck, M.A., Oh, W.K., et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetologia 64 (2021), 2359–2366.
Yu, Z., Li, P., Li, P., Zhang, H., Zhang, Y., Meta-analysis of long-term relapse rate of type 2 diabetes following initial remission after Roux-en-Y gastric bypass. Obes Surg 31 (2021), 5034–5043.
Borgeraas, H., Hofso, D., Hertel, J.K., Hjelmesaeth, J., Comparison of the effect of Roux-en-Y gastric bypass and sleeve gastrectomy on remission of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Obes Rev, 21, 2020, e13011.
Sudlow, A., le Roux, C.W., Pournaras, D.J., Review of multimodal treatment for type 2 diabetes: combining metabolic surgery and pharmacotherapy. Ther Adv Endocrinol Metab, 10, 2019, 2042018819875407.
Sudlow, A., Pournaras, D.J., le Roux, C.W., Combining metabolic surgery with medications for type 2 diabetes: is there a benefit?. J Bariatr Surg 2 (2023), 13–19.
Kim, J., Kwon, H.S., Not control but conquest: strategies for the remission of type 2 diabetes mellitus. Diabetes Metab J 46 (2022), 165–180.
Cheong, A.J.Y., Teo, Y.N., Teo, Y.H., Syn, N.L., Ong, H.T., Ting, A.Z.H., et al. SGLT inhibitors on weight and body mass: a meta-analysis of 116 randomized-controlled trials. Obesity 30 (2022), 117–128.
Mori, Y., Duru, O.K., Tuttle, K.R., Fukuma, S., Taura, D., Harada, N., et al. Sodium-glucose cotransporter 2 inhibitors and new-onset type 2 diabetes in adults with prediabetes: systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 108 (2022), 221–231.
Kashyap, S.R., Kheniser, K., Aminian, A., Schauer, P., Le Roux, C., Burguera, B, Double-blinded, randomized, and controlled study on the effects of canagliflozin after bariatric surgery: a pilot study. Obes Sci Pract 6 (2020), 255–263.
Scheen, A.J., Bonnet, F., Efficacy and safety profile of SGLT2 inhibitors in the elderly: how is the benefit/risk balance?. Diabetes Metab, 49, 2023, 101419.
Mulla, C.M., Baloch, H.M., Hafida, S., Management of diabetes in patients undergoing bariatric surgery. Curr Diabetes Rep, 19, 2019, 112.
Busetto, L., Dicker, D., Azran, C., Batterham, R.L., Farpour-Lambert, N., Fried, M., et al. Obesity management task force of the European association for the study of obesity released "practical recommendations for the post-bariatric surgery medical management". Obes Surg 28 (2018), 2117–2121.
Mechanick, J.I., Apovian, C., Brethauer, S., Timothy Garvey, W., Joffe, A.M., Kim, J., et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 Update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Obesity 28 (2020), O1–O58.
Food and Drug Administration. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. 2015. https://www.fdagov/files/drugs/published/Drug-Safety-Communication–FDA-warns-that-SGLT2-inhibitors-for-diabetes-may-result-in-a-serious-condition-of-too-much-acid-in-the-blood pdf Last accessed May 10, 2023. 2015.
National Institute for health and Care Excellence (NICE). Type 2 diabetes in adults: management. [NICE Guideline No.28]. https://www.nice.org.uk/guidance/ng28/chapter/Recommendations#drug-treatment. Last accessed on May 10, 2023. 2022.
Handelsman, Y., Henry, R.R., Bloomgarden, Z.T., Dagogo-Jack, S., DeFronzo, R.A., Einhorn, D., et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract 22 (2016), 753–762.
British Obesity and Metabolic Surgery Society (BOMSS). BOMSS patient safety committee alert on the use of gliflozins. https://www.rcsed.ac.uk/news-public-affairs/news/2022/march/bomss-patient-safety-committee-alert-on-the-use-of-gliflozins. Last accessed on May10, 2023. 2022.